Tuesday 14 July 2026

One To Watch

Gilgamesh Pharmaceuticals

A clinical-stage neuroscience company developing best-in-class, rapid-acting treatments for mental health disorders.

Company Overview

Want to Update your Company's Profile?


Latest Gilgamesh Pharmaceuticals News

AbbVie to acquire Gilgamesh’s bretisilocin
26 August 2025
Gilgamesh touts positive Phase IIa results for GM-2505 in MDD
28 May 2025
AbbVie dips toe into neuroplastogens with Gilgamesh deal
13 May 2024
$14 million award for Gilgamesh to study novel addiction therapy
14 March 2024
More Gilgamesh Pharmaceuticals news >


Today's issue

Q32 Bio reports top-line results for bempikibart in alopecia areata
Biotechnology
Q32 Bio reports top-line results for bempikibart in alopecia areata
13 July 2026
Biotechnology
Eisai touts latest findings for etalanetug in Alzheimer's
13 July 2026
Pharmaceutical
Pfizer names Danna Breen to lead obesity discovery as Kendra Bence exits
13 July 2026
Biotechnology
Stoke Tx appoints Thomas McCauley as CSO
13 July 2026
Biotechnology
GSK posts positive interim results for Jemperli in rectal cancer
13 July 2026
Pharmaceutical
GHIT Fund commits $18 million to advance six global infectious disease R&D programs
13 July 2026
Biotechnology
Caixa Capital Risc rebrands as Criteria Capital Risc
13 July 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze